Fumaric acid
|
Basic information |
| Metabolite name | Fumaric acid |
 | HMDB0000134 |
 |
C00122 |
 |
444972 |
| Synonyms | Fumarate |
| No. of studies | 33 |
|
Basic information |
| Metabolite name | Fumaric acid |
| HMDB0000134 |
|
C00122 |
|
444972 |
| Synonyms | Fumarate |
| No. of studies | 33 |
|
Relationship between Fumaric acid and depression (count: 33) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M105 | Type1 | sCSDS group vs. control group | Liver | C57BL/6JJmsSlc mouse | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type2 | CMS + venlafaxine group vs. CMS group | Ventral hippocampus | Wistar rat | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M116 | Type3 | LY group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Down |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Up |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Urine | Wistar rat | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M881 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M894 | Type1 | electromagnetic field exposure group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |